Is It Ozempic Gastroparesis? Understanding Your Symptoms

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Legal Inquiry

If you're experiencing persistent nausea, vomiting, or abdominal pain after starting Ozempic, you may wonder if it's gastroparesis. Distinguishing between temporary side effects and a true diagnosis of delayed gastric emptying is crucial. Building on decades of research into medication safety, this page clarifies the symptoms versus the diagnosis of Ozempic-associated gastroparesis.

Understanding Ozempic and Its Gastrointestinal Risks

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes and, in higher doses, for chronic weight management. Among the adverse effects associated with its use, gastrointestinal complications are prominent, and there is growing concern about a specific condition: gastroparesis. Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. The clinical presentation can range from mild discomfort to severe malnutrition and hospitalization. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The mechanistic link between Ozempic and gastroparesis lies in the drug's pharmacological action. GLP-1 receptor agonists slow gastric motility as part of their glucose-lowering effect, which can become pathological in some individuals, resulting in sustained gastroparesis even after drug discontinuation. Evidence from clinical trials underscores the frequency of gastrointestinal adverse reactions with Ozempic. In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, specific gastrointestinal adverse reactions with a frequency of less than 5% were associated with Ozempic, including dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate that gastrointestinal effects are dose-dependent and can be severe enough to lead to treatment discontinuation.

Adequacy of Warnings and Legal Implications

The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk consideration. The prescribing information for Ozempic includes warnings about serious hypersensitivity reactions such as anaphylaxis and angioedema, but it does not explicitly list gastroparesis as a warning or caution (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While the label notes gastrointestinal adverse reactions, it does not specifically address the risk of delayed gastric emptying or gastroparesis as a distinct adverse event. This omission may leave patients and healthcare providers unaware of the potential for a chronic condition that can persist after stopping the medication. For affected patients, this raises questions about whether the manufacturer provided sufficient information to allow informed decision-making and early recognition of symptoms. For individuals who develop gastroparesis after using Ozempic, attorney-related considerations become relevant. Patients may seek legal recourse if they believe the drug's labeling was inadequate in warning about the risk of gastroparesis. Key factors in such cases include the timeline between exposure and documented harm. Gastrointestinal symptoms often emerge during dose escalation, as noted in clinical trials, but the progression to full gastroparesis may occur over weeks to months. Documenting the onset of symptoms relative to Ozempic initiation is crucial for establishing causation. Patients should maintain detailed medical records, including dates of drug use, symptom onset, diagnostic tests (e.g., gastric emptying studies), and any hospitalizations. Legal claims may focus on failure to warn, design defect, or negligence in post-market surveillance. In summary, Ozempic is associated with a high rate of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The mechanistic pathway involves GLP-1 receptor agonist-induced slowing of gastric motility, which can become pathological. The current labeling does not explicitly warn about gastroparesis, potentially leaving patients at risk. For those affected, consulting with an attorney experienced in pharmaceutical litigation may be appropriate to evaluate the adequacy of warnings and the timeline of harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it linked to Ozempic?

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Ozempic (semaglutide) slows gastric motility as part of its mechanism, which can become pathological in some individuals, resulting in sustained gastroparesis even after drug discontinuation. Clinical trials show high rates of gastrointestinal adverse reactions with Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does Ozempic's label warn about gastroparesis?

No, the prescribing information for Ozempic does not explicitly list gastroparesis as a warning or caution. While it notes gastrointestinal adverse reactions, it does not specifically address the risk of delayed gastric emptying or gastroparesis as a distinct adverse event (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What legal options do I have if I developed gastroparesis after taking Ozempic?

If you developed gastroparesis after using Ozempic, you may seek legal recourse based on failure to warn, design defect, or negligence. Key factors include documenting the timeline of exposure and harm. Consulting with an attorney experienced in pharmaceutical litigation can help evaluate the adequacy of warnings and the strength of your case.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.